Wall Street analysts expect Eyenovia Inc (NASDAQ:EYEN) to report earnings of ($0.47) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Eyenovia’s earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.53). Eyenovia posted earnings of ($0.33) per share in the same quarter last year, which would suggest a negative year over year growth rate of 42.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 13th.
On average, analysts expect that Eyenovia will report full-year earnings of ($1.80) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.62). For the next fiscal year, analysts forecast that the company will report earnings of ($1.54) per share, with EPS estimates ranging from ($1.96) to ($1.06). Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Eyenovia.
Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01.
NASDAQ:EYEN traded down $0.05 during midday trading on Friday, reaching $3.16. The stock had a trading volume of 844 shares, compared to its average volume of 259,182. The firm has a market capitalization of $52.77 million, a PE ratio of -1.74 and a beta of 1.16. The business has a fifty day moving average price of $3.82. Eyenovia has a 1-year low of $2.40 and a 1-year high of $6.98.
In other Eyenovia news, Director Curt H. Labelle acquired 17,985 shares of Eyenovia stock in a transaction dated Thursday, July 11th. The stock was bought at an average cost of $2.78 per share, with a total value of $49,998.30. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Tsontcho Ianchulev acquired 233,813 shares of Eyenovia stock in a transaction dated Thursday, July 11th. The shares were acquired at an average cost of $2.78 per share, with a total value of $650,000.14. The disclosure for this purchase can be found here. Company insiders own 43.10% of the company’s stock.
An institutional investor recently bought a new position in Eyenovia stock. Bank of New York Mellon Corp acquired a new stake in Eyenovia Inc (NASDAQ:EYEN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned about 0.11% of Eyenovia at the end of the most recent reporting period. Institutional investors and hedge funds own 7.88% of the company’s stock.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More: What are economic reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.